GlycoMimetics Inc
(NAS:GLYC)
$
0.3131
-0.0079 (-2.46%)
Market Cap: 20.19 Mil
Enterprise Value: 6.06 Mil
PE Ratio: 0
PB Ratio: 1.78
GF Score: 30/100 GlycoMimetics Inc at Stifel Virtual Healthcare Conference Transcript
Nov 17, 2020 / 01:00PM GMT
Release Date Price:
$4.02
(+6.63%)
Operator
My name is Ellen Sands, and I'm a biotechnology associate at Stifel. And today, I have the pleasure of speaking with Rachel King, the CEO of GlycoMimetics. (Operator Instructions)
So Rachel, thanks for being here today, and...
Rachel K. King
GlycoMimetics, Inc. - President, CEO & Director
Sure.
Ellen Sands
Stifel, Nicolaus & Company, Incorporated, Research Division - Research Analyst
And maybe to start, you can give a brief overview of GlycoMimetics and just touch on the pipeline at a high level, and then we can dive in after that.
Rachel K. King
GlycoMimetics, Inc. - President, CEO & Director
Sure. So we're a clinical stage company. We've got a late-stage program now in AML, which is in 2 Phase III registration trials, one is treating newly diagnosed patients who are fit for chemotherapy, and the other treating relapsed/refractory patients also fit for chemotherapy. That's our most advanced program.
We also have a program that recently
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot